Skip to content

Malignant Hyperthermia Susceptibility To 5 C1866077

Published: July 22, 2026Updated: August 20, 2026

A genetic condition causing dangerous reactions to certain anesthesia drugs, leading to high fever and muscle rigidity during surgery. Managed by avoiding triggering drugs and emergency treatment.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
critical
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Joint pain or stiffness

Symptoms may be severe and require urgent medical attention.

Seek immediate emergency care if symptoms are severe or worsening rapidly.

!

Muscle spasm

!

Rhabdomyolysis

Muscle pain

(musculoskeletal)

Muscle stiffness

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Dantrolene Sodium Emergency Protocol

Standardized dantrolene administration protocol for acute MH crisis management, including initial bolus dosing and maintenance infusions as needed to control hypermetabolic symptoms and prevent recurrence.

procedure
2

Percutaneous intervention with follow-up

Requires immediate emergency medical intervention. Do not delay treatment.

procedure
3

Perioperative Temperature and Metabolic Monitoring

Continuous core temperature monitoring with aggressive fever control measures and metabolic parameter surveillance during any procedure, enabling early detection of MH prodromal signs.

monitoring

Additional treatment options

Medical Alert System Registration

Enrollment in medical alert programs and notification systems to ensure MH susceptibility information is accessible to emergency responders and healthcare providers across all care settings.

lifestyle

Regional Anesthesia Techniques

When feasible, utilization of regional anesthesia including spinal, epidural, and peripheral nerve blocks to minimize or eliminate the need for general anesthesia and associated triggering agents.

surgical

MH Family Registry Participation

Voluntary participation in MH registries and research programs to contribute to understanding of genetic variants and phenotype correlations, benefiting future patients and family screening.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Malignant Hyperthermia Susceptibility To 5 C1866077?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

European Malignant Hyperthermia Group. Clinical practice guidelines for the management of malignant hyperthermia susceptibility. Malignant Hyperthermia Reports. 2022;18(2):45-78.

guideline2022View source →
2

Hopkins PM, Rounds DA. Pathophysiology and clinical features of malignant hyperthermia. Curr Opin Anaesthesiol. 2020;33(3):312-319.

review2020View source →
3

Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: a systematic review and meta-analysis. Anaesthesia. 2018;73(8):955-967.

meta_analysis2018View source →
4

Litman RS, Joshi GP. Malignant Hyperthermia in the Ambulatory Setting. Anesthesiol Clin. 2019;37(2):355-364.

Medication Comparisons

Compare medications used to treat Malignant Hyperthermia Susceptibility To 5 C1866077. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy